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Recently, theP86Lalteration inCALHM1 (calciumhomeostasismodulator-1)was reported tobeassociated
with Alzheimer’s disease (AD). Moreover, the risk allele increased amyloid- (A) levels in conditioned
media from cultured cells. Therefore, we hypothesized that CALHM1 P86L may modulate A or tau levels
in cerebrospinal ﬂuid (CSF). Nearly 200 individuals with AD or other cognitive disorders were included
for CSF analysis and CALHM1 genotyping. No signiﬁcant differences in CSF levels of A42, tau or phospho-
tau were found across the various CALHM1 genotypes. In conclusion, we found no evidence that CALHM1
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lzheimer’s disease (AD) is a genetically heterogeneous disorder
elieved to be initiated by the deposition of amyloid- (A) pep-
ides in the brain. Apart from rare familial early-onset forms caused
y mutations in the genes for amyloid precursor protein (APP), pre-
enilin 1 (PSEN1) and presenilin 2 (PSEN2) several risk genes have
een suggested, of which only a fraction show consistent results
pon meta-analysis [1]. Of these, only the apolipoprotein E (APOE)
as been established to modulate the risk for AD. Carriers of one
POE4allelehavea3–4 times increaseddisease riskwhereasAPOE
4 homozygotes are 10–15 times more susceptible to AD [10].The pathogenic mechanisms underlying the association
etween APOE 4 and AD risk are only partly understood, but
everal lines of evidence suggest that the 4 allele increases the
eposition of A, particularly of more aggregation-prone A42
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oi:10.1016/j.neulet.2009.12.011peptides. Consistent with this, AD patients with the APOE 4
allele have increased levels of aggregated A in brain (as shown
by PET-PIB imaging) [6] along with decreased levels of A42 in
cerebrospinal ﬂuid (CSF) [4,5,11,12]. The cause for decreased CSF
A42 in AD is not completely understood, although it has been
assumed to reﬂect the increased deposition of A plaques in the
diseased brain.
Recently, a novel gene on chromosome 10 (10q24.33) was
reported to modulate the risk for late-onset sporadic AD [3]. In that
study, several independent case-control cohorts were genotyped
for a Pro to Leu alteration at codon 86 (P86L; rs2986017) in the gene
for calcium homeostasis modulator-1 (CALHM1), a transmembrane
glycoprotein. Heterozygotes for the leucine-allele were found to
have approximately 30% increased risk for AD, whereas homozy-
gotes appeared to have an almost 80% risk increase [3] as compared
to proline homozygotes. Much like most other proposed genetic
associations inAD, the relevanceof thispotential risk effect remains
to be investigated, as no association with disease risk was found in
at least three independent follow-up studies [2,8,9]. According to
266 V. Giedraitis et al. / Neuroscience Letters 469 (2010) 265–267
Table 1




n (%) 37 (55.2) 25 (37.3) 5 (7.5) 67
t-tau [ng/ml] (SD) 607.3 (440.8) 457.2 (219.3) 498.0 (182.0) 543.1 (361.6)
p-tau [ng/ml] (SD) 94.2 (61.1) 72.2 (33.5) 63.8 (17.5) 83.7 (51.0)
A42 [ng/ml] (SD) 469.4 (242.3) 519.2 (240.2) 530.0 (218.2) 492.5 (237.8)
Finnish
n (%)a 77 (64.7) 38 (31.9) 4 (3.4) 119











lp-tau [ng/ml] (SD) 66.8 (21.7)
A42 [ng/ml] (SD) 485.6 (191.7) 4
a Number of available samples for t-tau and p-tau measurements: CC=28, CT=1
he biochemical assessments, CALHM1 P86L risk allele was found
o affect APP processing in a calcium-dependent fashion, and to
ncrease A levels in the conditioned media of cultured Chinese
amster ovary (CHO) cells [3]. This was attributed to an impair-
ent of the normal function of CALHM1, which would result in
n increase of extracellular levels of A. Collectively, these data
ig. 1. Normalized CSF levels of A42, total tau and p-tau with respect to the CALHM1 P
evel of the combined sample set.5.2) 67.0 (0) 71.0 (31.5)
52.3) 552.2 (124.5) 477.0 (177.5)
TT=1.
suggest that CALHM1 may act as an important regulator of A
metabolism also in the human brain.
In this study, we investigated whether or not the proposed
CALHM1 P86L risk allele affects CSF levels of A42, total tau and
phospho-tau in patients with AD or other cognitive conditions. CSF
from a total of 186 individuals was analyzed and all cases were
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enotyped for CALHM1 P86L, allowing us to investigate the inﬂu-
nce of CALHM1 P86L on CSF biomarker levels.
A total of 70 (age± SD 66.8±8.2 years, 48% females) Swedish
ases, recruited from the Memory Disorder Unit at Uppsala Uni-
ersity Hospital, underwent lumbar puncture as part of clinical
ementia investigation. The CALHM1 genotype was successfully
etermined on 67 of the cases. Of these, 18 patients were diag-
osed with probable AD based on NINCDS-ADRDA criteria [7]. The
emaining 49 patients were diagnosed with other cognitive diag-
oses, such as mild cognitive impairment (n=34), non-speciﬁed
ementia (n=1), subjectivememory disturbance (n=10), and fron-
otemporal dementia (n=4). Moreover, 119 AD cases (age-at-onset
0.5±7.1 years, 72% females) from eastern Finland underwent
umbar puncture as part of a dementia investigation at the Depart-
ent of Neurology of Kuopio University Hospital. All patients
ulﬁlled the NINCDS-ADRDA criteria for probable AD [7]. Informed
onsentwasobtained fromall Swedish andFinnish subjects and the
tudy was approved by the Regional Ethical Committee in Uppsala
nd The Ethics Committee of Kuopio University Hospital/Kuopio
niversity, respectively.
Genotypes for the CALHM1 P86L (rs2986017) variant were gen-
rated as previously described [2], either by single-base extension
ollowedbyhigh-efﬁciencyﬂuorescencepolarization (HEFP)detec-
ion, or by direct sequencing. Genotyping efﬁciency was 96%, and
he error rate below 0.2%. The Swedish and Finnish CSF samples
ere analyzed for A42 (INNOTEST® ß-AMYLOID(1-42), Innogenet-
cs, Ghent, Belgium). Moreover, the samples were also analyzed
or total tau (t-tau, INNOTEST hTAU Ag, Innogenetics), and tau
hosphorylated at Thr181 (p-tau, INNOTEST PHOSPHO-TAU(181P),
nnogenetics).
Kruskal–Wallis ANOVA followed by a Mann–Whitney U test
as used to investigate possible differences in CSF A42, tau or
-tau between subjects with the different CALHM1 genotypes. In
rder to combine data from Swedish and Finnish samples, marker
evels were normalized based on the mean concentration of each
iomarker in the CC genotype carriers. Power analysis indicated a
ower of 0.84 to detect a 1.2-fold increase in A42 levels between
he CALHM1 CC and CT genotypes. However, due to the lower
umber of samples and higher variation power to detect 1.2-fold
ncrease in tau and p-tau was only 0.36 and 0.47, respectively.
ll statistical analyses were performed by the Statistica software
StatSoft Inc. Tulsa, OK, USA).
When analyzing the Swedish and Finnish cohorts separately,
SF levels of A42, total tau, and p-tau did not differ with respect
o theCALHM1genotype (Table1).AlthoughabsoluteCSFA42, tau,
nd p-tau concentrations were very similar between the Swedish
nd Finnish groups (Fig. 1), their respective levels were normal-
zed within each cohort, allowing a combined analyses of samples.
hen analyzing the combined Swedish–Finnish sample set, no
igniﬁcant differences were detected between heterozygous and
omozygous carriers of the “risk allele” (leucine or T) as compared
o subjects homozygous for the “wild-type” (proline or C) allele.
inally, no differenceswere foundwhen analyzing the AD and non-
D subgroups separately.
Based on recently described ﬁndings [3], we investigated
hether CSF levels of A42 are affected between carriers and non-
arriers of theproposedADrisk allele (P86L) inCALHM1. In addition,
e also analyzed total and phosphorylated tau levels, since both
f these biomarkers are known to negatively correlate with CSF
 levels. However, the results should be interpreted cautiously,
ecause of the low sample numbers and high inter-individual vari-
[etters 469 (2010) 265–267 267
ations in biomarker levels. When analyzing CSF A42, t-tau and
p-tau from Swedish and Finnish patients, we did not detect any
signiﬁcant differences with respect to the CALHM1 genotype. Fur-
thermore, separate subgroup analyses on AD (n=18) and non-AD
(n=48) cases in the Swedish cohort also failed to show any corre-
lation between the CALHM1 genotype status and the investigated
CSF biomarkers. In conclusion, we did not ﬁnd any evidence that
the CALHM1 P86L variation affects levels of A and tau in CSF from
cases with AD or other cognitive disorders.
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